Curriculum vitae - Daniela Maria Carmelita Rossi

Work address: Laboratory for Research on Neurodegenerative Disorders
Istituti Clinici Scientifici Maugeri SpA SB - IRCCS
Via Maugeri, 10
27100 Pavia (Italy)

EDUCATION

2017	National Scientific Qualification to function as University Professor (Human Anatomy – 05/H1), Italian Ministry for Education, University and Research (MIUR, Italy).
2001	Ph.D. in Natural Sciences, University of Zürich (Switzerland).
1997	Degree in Pharmacology (full marks cum laude), University of Milan (Italy).
1995	Degree in Pharmaceutical Chemistry (full marks), University of Milan.

EXPERIENCE AND TRAINING

2009 – present	Director, Laboratory for Research on Neurodegenerative Disorders, Istituti Clinici Scientifici Maugeri - IRCCS, Pavia (Italy).
2005 – 2009	Senior scientist at the Center of Excellence on Neurodegenerative Diseases, University of Milan (Italy)
2002 – 2005	EMBO long term fellow at the Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milan
1999 –2002	Research fellow at the MRC Prion Unit and Neurogenetics Department, Imperial College School of Medicine at St. Mary's, London (United Kingdom).
1997-1999	Research fellow at the Institute of Molecular Biology, University of Zurich (Switzerland)
1995-1997	Research fellow at the Department of Pharmacological Sciences, University of Milan.
1994 – 1995	Internship at the Center of Neuropharmacology c/o Institute of Pharmacological Sciences, University of Milan

HONORS AND AWARDS

2012	Best Platform Presentation Award at the "10th Annual ENCALS Meeting", Dublin – 25-27th May, 2012
2012	Best Scientific Poster Award at the "International Symposium on Biology and Translational Aspects of Neurodegeneration", Venice – March 12-14, 2012
2006 – 2009	Member of the Scientific Committee of the Center of Excellence on Neurodegenerative Diseases of the University of Milan
2005	Winner on competition of a Dean's Fellowship, University of Milan
2005	Chiron Young Prion Scientist Award
2003 – 2005	EMBO Long Term Fellowship

Autorizzo il trattamento dei dati personali presenti nel CV ai sensi del D. Lgs. 2018/101 e del GDPR (Regolamento UE 2016/679)

GRANTS

2023 – 2026	EU Joint Programme – Neurodegenerative Disease Research (JPND – DC4MND)
2018 – 2022	AFM – Téléthon (21565)
2014 – 2017	AFM – Téléthon (18221)
2012 – 2013	AFM – Téléthon (16177)
2009 – 2015	Italian Ministry of Health (RF-2009-1506142)
2005 – 2008	Italian Ministry for Education, University and Research (2006055930)
2005 - 2008	Telethon Foundation (GGP05244)
2003 – 2005	EMBO Long Term Fellowship (ALTF 279-2002)

CONFERENCE ORGANIZATION

2015	Co-Organizer, Symposium, "Role of Glial Cells in Rare Diseases", XII European Meeting on Glial Cells in Health and Disease, Bilbao (Spain)
2009	Co-Organizer, Symposium, "Astroglia in Health and Disease", XIII National Congress of the Italian Society for Neuroscience, Milan (Italy)

ACADEMIC ACTIVITIES

2020-present	Adjunct professor of Human Neuroanatomy in the course of Neurobiology at the University of Pavia
2017	Member of a doctoral dissertation defense committee at the Université catholique de Louvain (Belgium)
2002-2018	Scientific supervisor of 20 master's theses and 3 doctoral dissertations at the Universities of Milan and Pavia (Italy)
2002-2018	Teaching at the Universities of Milan and Pavia in the courses on Pharmacological Biotechnologies, Neuropsychopharmacology, Drugs for Rare Diseases, Neurobiology

PATENTS

2014 U.S. Patent (No. US 8,778,884 B2): "Glioprotectant Peptide for Use in the Treatment of Amyotrophic Lateral Sclerosis (ALS) and Methods Related Thereto" - Granting date: July 15, 2014.

2018 PCT Patent Application (No. PCT/IB2018/050425; EP18702344.5): "Biologically active fusion peptide for use in the treatment of Spinal Muscular Atrophy (SMA)" – Filing date: January 24, 2018.

EDITORIAL ACTIVITIES

Dr. Daniela Rossi is Associate Editor of the journal *Frontiers in Neurodegeneration,* a specialty of Frontiers in Neurology and Frontiers in Psychiatry, and Review Editor of *Frontiers in Molecular Neuroscience*, a specialty of Frontiers in Neuroscience.

THIRD MISSION

2009 Presentation on the "Molecular mechanisms of ALS: studies in experimental models" at the meeting of the Italian Association of Amyotrophic Lateral Sclerosis (AISLA Onlus Asti)

2018 5x1000 campaign of the Salvatore Maugeri Foundation in support of scientific research (https://www.youtube.com/watch?v=Vqgs51z1wxc) (Pavia)

2019 Presentation of the book "Il mio viaggio nella SLA. Un percorso di conoscenza e condivisione dei problemi dei malati" ("My journey through ALS. A journey of knowledge and sharing of the patients' problems") by Antonio Pinna at the Centro Puecher-Biblioteca Chiesa Rossa (Milan).

2019 Presentation on the “Malattie Neurodegenerative: innovazioni per la diagnosi e la cura” (“Neurodegenerative diseases: innovations for diagnosis and treatment”) for the ‘Researchers' Night’ at the Istituti Clinici Scientici Maugeri SpA SB - IRCCS (Pavia).

RESEARCH AREA AND INTERESTS

Present research interests involve the comprehension of the molecular mechanisms of neurodegeneration in various disorders of the CNS, particularly Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA), with the aim of identifying novel molecular pathways and targets for therapeutic intervention. Major attention is placed on the contribution to the neurodegenerative process of the neuronal microenvironment, particularly the neighbouring glial cells and related neuroinflammatory events. Preclinical models of disease have been developed and exploited by Daniela Rossi for mechanistic investigations and pharmacological trials over a period of 20 years. Furthermore, during the past 13 years, she has been strongly involved in the development of novel target-specific peptide therapeutics that are precisely designed to treat CNS disorders because they are endowed with properties that make them able to cross the blood-brain barrier. A pipeline of peptidic molecules has been currently developed for the treatment of multiple CNS diseases. One of these peptide therapeutics proved successful, at the preclinical level, in ALS and was patented in the United States (see U.S. Patent: US 8,778,884 B2, “Glioprotectant Peptide for Use in the Treatment of Amyotrophic Lateral Sclerosis (ALS) and Methods Related Thereto”). Additional peptides for the treatment of SMA have been recently protected by a PCT Patent Application, which has recently entered into the European Phase (see PCT/IB2018/050425, “Biologically active fusion peptide for use in the treatment of Spinal Muscular Atrophy”).

PUBLICATIONS

Papers in peer-revieweed journals

- Trotti, D., Volterra, A., Lehre, K.P., **Rossi, D.**, Gjesdal, O., Racagni, G., and Danbolt, N.C. (1995). Arachidonic Acid Inhibits a Purified and Reconstituted Glutamate Transporter Directly from the Water Phase and Not via the Phospholipid Membrane. ***J. Biol. Chem.***, 270, 9890 – 9895.
- Trotti, D., **Rossi, D.**, Gjesdal, O., Levy, L.M., Racagni, G., Danbolt, N.C. and Volterra, A. (1996). Peroxynitrite inhibits glutamate transporter subtypes. ***J. Biol. Chem.***, 271, 5976-5979.
- Trotti, D., Lodi Rizzini, B., **Rossi, D.**, Haugeto, O., Racagni, G., Danbolt, N.C. and Volterra, A. (1997). Neuronal and glial glutamate transporters possess an SH-based redox regulatory mechanism. ***Eur. J. Neurosci.***, 9, 1236-1243.
- Vesce S., Bezzi P., **Rossi D.**, Meldolesi J. and Volterra A. (1997). HIV-1 gp120 glycoprotein affects the astrocyte control of extracellular glutamate by both inhibiting the uptake and stimulating the release of the amino acid. ***FEBS Lett.***, 411, 107-109.
- Bezzi, P., Carmignoto, G., Pasti, L., Vesce, S., **Rossi, D.**, Lodi Rizzini, B., Pozzan, T. and Volterra, A. (1998). Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. ***Nature***, 391, 281-285.
- **Rossi, D.**, Cozzio, A., Flechsig, E., Klein, M.A., Rülicke, T., Aguzzi, A. and Weissmann, C. (2001). Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain. ***EMBO J.***, 20, 694-702.
- Montrasio, F., Cozzio A., Flechsig, E., **Rossi, D.**, Klein, M.A., Rülicke, T., Raeber, A.J., Vosshenrich, C.A.J., Proft, J., Aguzzi A. and Weissmann C. (2001). B lymphocyte-restricted expression of prion protein does not enable prion replication in prion protein knockout mice. ***Proc. Natl. Acad. Sci. USA***, 98, 4034-4037.
- Weissmann, C., Enari, M., Klöhn, P.C., **Rossi, D.** and Flechsig, E. (2002). Transmission and Propagation of Prions. ***J. Infect. Dis.*** 186 Suppl 2:S157-S165.
- Weissmann, C., Enari, M., Klöhn, P.C., **Rossi, D.** and Flechsig, E. (2002). Transmission of Prions. ***Proc. Natl. Acad. Sci. USA***, 99, 16378-162383.

- Weissmann, C., Enari, M., Klöhn, P.C., **Rossi, D.** and Flechsig, E. (2002). Molecular Biology of Prions. ***Acta Neurobiol. Exp. (Warsz)***, 62(3), 153-166.
- Flechsig, E., Hegyi, I., Leimeroth, R., Zuniga, A., **Rossi, D.**, Cozzio, A., Schwarz, P., Rülicke, T., Götz, J., Aguzzi, A. and Weissmann, C. (2003). Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia. ***EMBO J***., 22, 3095-3101.
- Anderson, L.*, **Rossi, D**.*, Linehan, J., Brandner, S., and Weissmann C. (2004). Transgene-driven expression of the Doppel protein in Purkinje cells causes Purkinje cell degeneration and motor impairment. ***Proc. Natl. Acad. Sci. USA***, 101, 3644- 3649. ***Contributed equally to this work**
- **Rossi, D.**, Brambilla, L., Valori, C., Bezzi, P., Giaccone, G, Capobianco, R., Mangieri, M., Kingston A. and Volterra A. (2005). Defective TNFalpha-dependent control of astrocyte glutamate release in a transgenic mouse model of Alzheimer's disease. ***J. Biol. Chem****.,* 280, 42088-42096.
- Vesce, S., **Rossi, D.**, Brambilla L. and Volterra, A. (2007). Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterised by neuroinflammation. ***Int Rev Neurobiol.***, 82, 57-71.
- **Rossi, D.***, Brambilla, L., Valori, C.F., Crugnola, A., Roncoroni, C., Yokota, T., Bredesen, D.E., and Volterra A. (2008). Focal degeneration of astrocytes in amyotrophic lateral sclerosis. ***Cell Death Differ.***, 15, 1691-1700. ***Corresponding author**
- Barenco, M.G., Valori, C., Roncoroni, C., Loewer, J., Montrasio, F., **Rossi, D.** (2009). Deletion of the amino-terminal domain of the prion protein does not impair prion protein-dependent neuronal differentiation and neuritogenesis. ***J Neurosci Res.***, 87, 806-819.
- **Rossi, D.** and Volterra, A. (2009). Astrocytic dysfunction: insights on the role in neurodegeneration. ***Brain Res Bull.***, 80, 224-232.
- **Rossi, D.***, Martorana, F., Brambilla, L. (2011). Implications of Gliotransmission for the Pharmacotherapy of CNS Disorders. ***CNS Drugs***, 25(8), 641-658. ***Corresponding author**
- Martorana, F., Brambilla, L., Valori C.F., Bergamaschi, C., Roncoroni, C., Aronica, E., Volterra, A., Bezzi, P., and **Rossi D.** (2012). The BH4 domain of Bcl-X_L rescues astrocyte degeneration in Amyotrophic Lateral Sclerosis by modulating intracellular calcium signals. ***Hum Mol Genet.***, 21(4), 826-840.
- Benedusi, V., Martorana, F., Brambilla, L., Maggi, A., and **Rossi, D.** (2012). The Peroxisome Proliferator-Activated Receptor γ (PPARγ) controls natural protective mechanisms against lipid peroxidation in Amyotrophic Lateral Sclerosis. ***J. Biol. Chem.***, 287(43), 35899-35911.
- Brambilla, L., Martorana, F., and **Rossi, D.** (2013). Astrocyte signalling and neurodegeneration: new insights into CNS disorders. ***Prion***, 7(1), 28-36.
- Valori, C.F., Brambilla, L., Martorana, F., and **Rossi, D.** (2014). The Multifaceted Role of Glial Cells in Amyotrophic Lateral Sclerosis. ***Cell Mol Life Sci.***, 71(2), 287-297.
- Pansarasa, O., **Rossi, D.**, Berardinelli, A., Cereda, C. (2014). Amyotrophic lateral sclerosis and skeletal muscle: an update. ***Mol Neurobiol.,*** 49(2), 984-990.
- **Rossi, D.** (2015). Astrocyte physiopathology: at the crossroads of intercellular networking, inflammation and cell death. ***Prog Neurobiol.***, 130, 86-120.
- Martorana, F., Guidotti, G., Brambilla, L., **Rossi D.** (2015). Withaferin A inhibits nuclear factor-kappaB-dependent pro-inflammatory and stress response pathways in the astrocytes. ***Neural Plasticity***, 2015:381964. doi: 10.1155/2015/381964. Epub 2015 Jul 21.
- Brambilla, L., Guidotti, G., Martorana, F., Iyer, A.M., Aronica, E., Valori, C.F., **Rossi D.** (2016). Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis. ***Hum Mol Genet.***, 25(14), 3080-3095.
- Guidotti, G., Brambilla, L., and **Rossi, D.** (2017). Cell-penetrating peptides: from basic research to clinics. ***Trends Pharmacol Sci.***, 38(4), 406-424.
- **Rossi, D.**, Volanti, P., Brambilla, L., Colletti, T., Spataro, R., and La Bella V. (2018). CSF Neurofilament Proteins as diagnostic and prognostic biomarkers for Amyotrophic Lateral Sclerosis. ***J Neurol.***, 265(3), 510-521.

- Stanga, S., Brambilla, L., Tasiaux, B, Dang., H.A., Ivanoiu., A., Octave, J.N., **Rossi, D.**, van Pesch, V. and Kienlen-Campard P. (2018). A role for GDNF and soluble APP as biomarkers of Amyotrophic Lateral Sclerosis pathophysiology. ***Front Neurol.***, 2018 May 30;9:384. doi: 10.3389/fneur.2018.00384.
- Brambilla, L., Martorana, F., Guidotti, G., and **Rossi, D.** (2018). Dysregulation of Astrocytic HMGB1 Signaling in Amyotrophic Lateral Sclerosis. ***Front Neurosci.***, 29 August 2018. https://doi.org/10.3389/fnins.2018.00622.
- Guidotti, G. Brambilla, L., and **Rossi, D.** (2019). Peptides in clinical development for the treatment of brain tumors. ***Curr Opin Pharmacol.***, 47, 102–109.
- Valori, C.F., Guidotti, G., Brambilla, L., and **Rossi, D.** (2019). Astrocytes: Emerging Therapeutic Targets in Neurological Disorders. ***Trends Mol Med.*,** 25(9), 750-759.
- Valori, C.F., Guidotti, G., Brambilla, L., and **Rossi, D.** (2019). Astrocytes in Motor Neuron Diseases. ***Adv Exp Med Biol.***, 1175, 227-272.
- Norante, R.P., Peggion, C., **Rossi, D.**, Martorana, F., De Mario, A., Lia, A., Massimino, M.L., and Bertoli, A. (2019). ALS-Associated SOD1(G93A) Decreases SERCA Pump Levels and Increases Store-Operated Ca2+ Entry in Primary Spinal Cord Astrocytes from a Transgenic Mouse Model. ***Int J Mol Sci.***, Oct 17;20(20). pii: E5151. doi: 10.3390/ijms20205151.
- Guidotti, G., Brambilla, L., and **Rossi, D.** (2020). Exploring novel molecular targets for the treatment of high-grade astrocytomas using peptide therapeutics: an overview. ***Cells***, 9, 490; doi:10.3390/cells9020490.
- Guidotti, G., Scarlata, C., Brambilla, L., and **Rossi, D.** (2021). Tumor Necrosis Factor alpha in Amyotrophic Lateral Sclerosis: Friend or Foe? ***Cells***, 10, 518; doi:10.3390/cells10030518.
- Cutarelli, A., Martínez-Rojas, V.A., Tata, A., Battistella, I., **Rossi, D.**, Arosio, D., Musio, C., and Conti, L. (2021). A Monolayer System for the Efficient Generation of Motor Neuron Progenitors and Functional Motor Neurons from Human Pluripotent Stem Cells. ***Cells***, 10, 1127; doi:10.3390/cells10051127.
- Valori, C.F., Possenti, A., Brambilla, L., and **Rossi, D.** (2021). Challenges and Opportunities of Targeting Astrocytes to Halt Neurodegenerative Disorders. ***Cells***, 10, 2019; doi:10.3390/cells10082019.
- Begenisic, T., Pavese, C., Aiachini, B., Nardone, A., and **Rossi, D.** (2021). Dynamics of biomarkers across the stages of traumatic spinal cord injury - Implications for neural plasticity and repair. ***Restor Neurol Neurosci.***, 39(5), 339-366; doi:10.3233/RNN-211169.
- Ferrari, F.*, **Rossi, D.***, Ricciardi, A.*, Morasso, C. Brambilla, L., Albasini, S., Vanna, R., Fassio, C., Begesenic, T., Loi, M., Bossi, D., Zaliani, A., Alberici, E., Lisi, C., Morotti, A., Cavallini, A., Mazzacane, F., Nardone, A., Corsi, F., Truffi, M. (2023). Quantification and prospective evaluation of serum NfL and GFAP as blood-derived biomarkers of outcome in acute ischemic stroke patients. ***J Cereb Blood Flow Metab.***; doi:10.1177/0271678X231172520. ***Contributed equally to this work.**
- Valori, C.F., Sulmona, C., Brambilla, L., and **Rossi, D.** (2023). Astrocytes: dissecting their diverse roles in amyotrophic lateral sclerosis and frontotemporal dementia. ***Cells,*** 12, 1450; doi:10.3390/cells12111450.
- De martini, L.B., Sulmona, C., Brambilla, L., and **Rossi, D.** (2023). Cell-Penetrating Peptides as Valuable Tools for Nose-to-Brain Delivery of Biological Drugs. ***Cells,*** 12, 1643; https://doi.org/10.3390/cells12121643.

Book chapters

- Trotti, D., Danbolt, N.C., Lodi Rizzini, B., Bezzi, P., **Rossi, D.**, Racagni, G. and Volterra, A. (1996). Glutamate transporters: molecular mechanisms of functional alteration and role in the development of excitotoxic neuronal injury. *Neurodegenerative diseases,* ed. Gary Fiskum, Plenum Press, New York.

- Trotti, D., **Rossi, D.**, Lodi Rizzini, B., Bezzi, P., Danbolt, N.C., Racagni, G. and Volterra, A. (1996). Molecular mechanisms of functional alteration of glutamate transporters and relevance to neuropathology. *Preclinical and clinical strategies for the treatment of neurodegenerative, cerebrovascular and mental disorders,* Int. Acad. Biomed. Drug Res. Basel, Karger, **11**, 41-48.
- Weissmann, C., Shmerling, D., **Rossi, D.**, Cozzio, A., Hegyi, I., Fischer, M., Leimeroth, R. and Flechsig, E. (2001). Structure-function analysis of prion protein. *New challenges to health: the threat of virus infection*, ed. G.L. Smith, W.L. Irving, J.W. McCauley, D.J. Rowlands, Cambridge University Press.
- Weissmann, C., Flechsig, E., **Rossi, D.**, Enari, M. (2002). Molecular Genetics of Trasmissible Spongiform Encephalopathies: An Overview. *Nova Acta Leopoldina,* NF 87, Nr. 327, S. 15-24.
- **Rossi, D.**, Bezzi, P., Domercq, M., Brambilla, L., Meldolesi, J., and Volterra, A. (2004). Contribution of Astrocyte Glutamate Release to Excitotoxicity. *Excitotoxicity in Neurological Disorders: New therapeutic challenge.* C. Ferrarese and F. Beal Eds, Kluwer Press.
- **Rossi, D.** & Volterra, A. (2011). Astrocyte-Neuron Communication: What Goes Wrong in Pathology? *Astrocytes: Wiring the Brain.* E. Scemes and D.C. Spray Eds, CRC Press.
- Valori, C.F., Brambilla, L., and **Rossi, D.** (2014). Amyotrophic Lateral Sclerosis: a glial perspective. *Pathological potential of neuroglia: Possible new targets for medical intervention.* V. Parpura and A. Verkhratsky Eds, Springer.

Selected abstracts of presentations at national and international meetings

- **Rossi,D.**, Brambilla, L., Valori, C.F., Roncoroni, C., Crugnola, A., Yokota, T., Bredesen, D.E., and Volterra, A.
  Focal Degeneration of Glutamate-Vulnerable Astrocytes in Amyotrophic Lateral Sclerosis.
  19th International Symposium on ALS/MND - Birmingham (United Kingdom) November 3-5, 2008
- **Rossi, D.**
  Role of astroglia on motor neuron cell survival and death in ALS.
  IV Meeting on the MOLECULAR MECHANISMS OF NEURODEGENERATION - Milan (Italy) May 8-10, 2009
- **Rossi, D.**
  Meccanismi molecolari: studi in modelli sperimentali
  La Sclerosi Laterale Amiotrofica: la presa in carico globale dal laboratorio di ricerca al letto del malato.
  AISLA meeting - Asti (Italy) June 20, 2009
- **Rossi, D.**, Brambilla, L., Valori, C.F., Roncoroni, C., Martorana, F., Crugnola, A., Bredesen, D.E., and Volterra A.
  Astroglial degeneration in Amyotrophic Lateral Sclerosis
  National Congress of the Italian Society for Neuroscience – Milan (Italy), October 2-5, 2009
- Martorana F., Brambilla L., Valori C.F., Roncoroni C., Bergamaschi C., Volterra A., Bezzi P., **Rossi D.**
  Aberrant intracellular Ca^{2+} signalling correlates with astrocyte degeneration in Amyotrophic Lateral Sclerosis
  Joint congress of FEPS and Turkish Society of Physiological Sciences - Istanbul (Turkey), September 3-7, 2011
- **Rossi D.**
  Altered intracellular calcium signaling correlates with astrocyte degeneration in ALS
  10th Annual European Network for the Cure of ALS Meeting - Dublin (Ireland), May 25-27, 2012
- **Rossi D.**
  Astrocyte degeneration in Amyotrophic Lateral Sclerosis: mechanism and rescue
  4th Conference of the Mediterranean Neuroscience Society - Istanbul (Turkey), September 30 – October 3, 2012

- Brambilla L., Martorana F., Guidotti G., Valori C.F., Bezzi P., and Rossi D.
  Functional deficits of the astrocytes in Amyotrophic Lateral Sclerosis
  XII European Meeting on Glial Cells in Health Disease - Bilbao (Spain) – July 15-18, 2015
- **Rossi D.**
  Peptide Therapeutics for the Treatment of Neurological Disorders
  General States of Health Research – Italian Ministry of Health - Rome (Italy), April 27-28, 2016
- Brambilla L., Guidotti G., Martorana F., Iyer A.M., Aronica E., Valori C.F., **Rossi D.**
  Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis
  "More than neurons: towards a less neuronocentric view of brain disorders" Meeting - Turin (Italy), December 1-3, 2016
- **Rossi D.**
  Deciphering the astrocytic response in Amyotrophic Lateral Sclerosis
  Workshop: "Human stem cells derived astrocytes as a new platform for studying neurological disorders" - Prague (Czech Republic), April 4, 2017
- Brambilla L., Guidotti G., Martorana F., Aronica E., Valori C.F., Bezzi P. and **Rossi D.**
  Astrocytes as cell targets for therapeutic intervention in ALS
  38° Congresso Nazionale Società Italiana di Farmacologia - Rimini (Italy), October 25-28, 2017
- Brambilla L., Guidotti G., Martorana F., Iyer A.M., Aronica E., Valori C.F., **Rossi D.**
  Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis
  ABCD Meeting "From Stress Response to Development and Regeneration" - Pavia (Italy), September 28-29, 2018
- **Rossi D.**
  Sviluppo di nuove terapie peptidiche per la SMA
  SMA : Progressi e Nuove Sfide - Milan (Italy), October 11, 2018
- **Rossi D.**
  Molecular Biomarkers
  VI SIN Course – Degenerative diseases of the central nervous system - Virtual Meeting (Italy), October 22-23, 2020
- **Rossi D.**
  Motor neuron diseases: an overview of ALS and SMA
  Motor Neuron Diseases. Understanding the Pathogenetic Mechanisms to develop Therapies - Virtual Meeting (Turin, Italy), November 6-7, 2020
- **Rossi D.**
  Neurofilaments as biomarkers in neurodegenerative diseases
  Grandangolo 2021 – One Year of Neurology - Virtual Meeting (Naples, Italy), January 29-30, 2021
- **Rossi D.**
  Lo stato infiammatorio in neurologia. Agente nemico o alleato terapeutico?
  Convegno SINdem - Vicenza (Italy), April 22, 2022

Pavia, 29/04/2024